Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CV Sciences, Inc.CVSI · Entity 8316 | Director · Chief Executive Officer | February 18, 2025 | February 20, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CV Sciences, Inc.
Report date February 18, 2025 · Filed February 20, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2035-02-17 | Direct | 3,000,000 |
Reported balance
After 2025-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-18 · Grant · Acquired 3,000,000 · Balance 3,000,000 F1: The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from February 18, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after the termination of service. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from February 18, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after the termination of service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2025 Filed Feb 20, 2025 22:27 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 3,000,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0000950170-25-024328 · ownership.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2035-02-17 F1 · derivative.exercise_date: The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from February 18, 2025, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after the termination of service. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 21:25 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 3,000,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0000950170-24-076906 · ownership.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from June 20, 2024, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:44 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 2,500,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001510964-23-000009 · wf-form4_167908588567379.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500,000 Underlying: Common Stock · 2,500,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option is durational-based. No option shares are vested on the date of grant. The option shares vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from March 15, 2023, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $0.37 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 10 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2027-04-06 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F6 · derivative.exercise_date: The option is performance-based. 250,000 option shares were vested and exercisable on the date of cancellation. The remaining option shares were scheduled to vest and become exercisable in accordance with certain performance criteria which were not met at the date of cancellation. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,000,000 | Not disclosed Strike: $0.37 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 9 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2026-07-05 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F5 · derivative.exercise_date: The option is performance-based. 500,000 option shares were vested and exercisable on the date of cancellation. The remaining option shares were scheduled to vest and become exercisable in accordance with certain performance criteria which were not met at the date of cancellation. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 600,000 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 8 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600,000 shares Expires 2024-09-30 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F1 · derivative.exercise_date: The option is durational based. All option shares were vested and exercisable on the date of cancellation. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 7 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2025-05-20 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F1 · derivative.exercise_date: The option is durational based. All option shares were vested and exercisable on the date of cancellation. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 6 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2015-09-22 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F1 · derivative.exercise_date: The option is durational based. All option shares were vested and exercisable on the date of cancellation. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 100,000 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 5 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2027-03-14 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F4 · derivative.exercise_date: The option was fully vested on the date of grant. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 500,000 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 4 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2028-03-19 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 500,000 | Not disclosed Strike: $0.66 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 3 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 500,000 shares Expires 2029-02-19 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F1 · derivative.exercise_date: The option is durational based. All option shares were vested and exercisable on the date of cancellation. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,500,000 | Not disclosed Strike: $0.59 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 2 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2031-03-08 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F3 · derivative.exercise_date: The option is durational based. 750,000 option shares were vested and exercisable on the date of cancellation. Twenty-five (25%) of the option shares were scheduled to vest and become exercisable on September 1, 2022 and March 1, 2023, provided, that there was no termination of service as of such date. Read SEC document |
| March 30, 2022 Filed Apr 2, 2022 00:15 UTC | CV Sciences, Inc. CVSI · Entity 8316 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,500,000 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001510964-22-000026 · wf-form4_164885852291255.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500,000 shares Expires 2030-03-19 F2 · price: On March 30, 2022, the stock options were cancelled by mutual agreement of the reporting person and the issuer. The reporting person received an aggregate of $100 as consideration for the cancellation. F1 · derivative.exercise_date: The option is durational based. All option shares were vested and exercisable on the date of cancellation. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:01 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 1,500,000 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001510964-21-000006 · wf-form4_161550003123434.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2031-03-08 F1 · derivative.exercise_date: The option is durational-based. No option shares are vested on the date of grant. Twenty-five percent (25%) of the option shares vest and become exercisable on each of the following dates: September 1, 2021, March 1, 2022, September 1, 2022, and March 1, 2023, provided, that there has not been a termination of service as of such date. In no event will any unvested portion of the option vest or become exercisable for any additional option shares after a termination of service. Read SEC document |
| March 20, 2020 Filed Mar 25, 2020 01:50 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 1,500,000 | $0.33 Strike: $0.33 | $495,000.00 |
DisclosureSEC source: 0001510964-20-000016 · wf-form4_158510102097096.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 Underlying: Common Stock · 1,500,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The option is durational-based. 500,000 option shares vested on the grant date, 500,000 option shares vest and become exercisable on April 15, 2020 and the remaining 500,000 option shares vest and become exercisable on July 15, 2020, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | CV Sciences, Inc. CVSI · Entity 8316 | PurchaseCommon Stock | 15,000 | $1.65 | $24,750.00 |
DisclosureSEC source: 0001510964-19-000074 · wf-form4_157359269572210.xml · nonDerivative · entry 1 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: These shares were purchased in multiple transactions at a price of $1.65 per share. F2 · price: The reporting person undertakes to provide CV Sciences, Inc., any security holder of CV Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, the full information regarding the number of shares purchased at the price set forth in footnote (1) to this Form 4. Read SEC document |
| February 20, 2019 Filed Mar 19, 2020 22:59 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001510964-20-000012 · wf-form4_158465877181784.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-02-19 F1 · derivative.exercise_date: The option is durational-based. 250,000 option shares vested on the date of grant and the remaining 250,000 option shares vest and become exercisable on May 20, 2019, provided, however, that there has not been a termination of service as of such date. In no event will the option become exercisable for any additional option shares after a termination of service. Read SEC document |
| March 20, 2018 Filed May 9, 2018 00:26 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001683168-18-001235 · dowling_f4.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · CFO, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2028-03-19 F1 · derivative.underlying_shares: The stock options are fully-vested on the Date of Grant. Read SEC document |
| July 14, 2017 Filed Mar 28, 2018 12:01 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001683168-18-000770 · dowling_f4.xml · derivative · entry 2 Dowling Joseph D · CIK 0001611860 · CFO, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-04-06 F3 · derivative.underlying_shares: On April 7, 2017, the Reporting Person was granted an option to purchase 1,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) when the Company has final meeting minutes from a pre-IND meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (ii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iii) when the Company commences its first human dosing under the IND (50% vesting of the shares subject to the option). On July 14, 2017, the first performance criterion was met resulting in vesting of the option as to 250,000 shares. Read SEC document |
| July 14, 2017 Filed Mar 28, 2018 12:01 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001683168-18-000770 · dowling_f4.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · CFO, Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2026-07-05 F1 · derivative.underlying_shares: On July 6, 2016, the Reporting Person was granted an option to purchase 1,000,000 shares of the Issuer's Common Stock. The option is performance-based, and vests and becomes exercisable as follows: (i) the first time the Issuer completes development of a U.S. Food & Drug Administration ("FDA") current good manufacturing practice grade batch of successfully synthetically formulated Cannabidiol ("CBD") for use in drug development activities (25% vesting of the shares subject to the option); (ii) when the Company has final meeting minutes from a pre-investigational new drug application ("IND") meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical ingredient (25% vesting of the shares subject to the option); (iii) when the Company is granted an IND (25% vesting of the shares subject to the option); and (iv) when the Company commences its first human dosing under the IND (25% vesting of the shares subject to the option). F2 · derivative.underlying_shares: On July 14, 2017, the second performance criterion was met resulting in vesting of the option as to 250,000 shares. Read SEC document |
| March 15, 2017 Filed Mar 30, 2017 21:01 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-017748 · v462987_4.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option is fully vested on the date of grant. Read SEC document |
| October 05, 2016 Filed Oct 17, 2016 22:32 UTC | CV Sciences, Inc. CVSI · Entity 8316 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001683168-16-000331 · dowling_frm4.xml · derivative · entry 1 Dowling Joseph D · CIK 0001611860 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2026-07-05 F1 · balance_after: See remarks below. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.